The first test for the daily practice developed from the METAdiag platform.
METAglut1™ is an in Vitro Diagnostic Medical Device used to aid in the diagnosis of the GLUT1 Deficiency Syndrome (GLUT1DS). It is a regulated health product that bears the CE mark.
METAdiag project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 806038.
Puzzled by these neurological symptoms?
• Intractable epilepsy
• Movement disorders
• Developmental delays
An innovative blood test to fight GLUT1DS misdiagnosis and medical wandering at the earliest
“It is essential to diagnose as early as possible to allow prompt compensation, through the Ketogenic Diet, for the brain’s lack of fuel…”
“Early identification of children with the disease is important in order to avoid submitting them to possibly ineffective or potentially detrimental treatments with anticonvulsants”
V. De Giorgis, P. Veggiotti / Seizure 22 (2013) 803–811 – GLUT1 deficiency syndrome 2013: Current state of the art.
METAglut1™ provides a simple way to find patients faster
An underdiagnosed disease of estimated ca. 12,000 cases of GLUT1DS in EU and the USA, most remain undiagnosed
Several complex symptoms can be a clue pointing to a GLUT1DS condition:
→ Intractable epilepsy, in particular early onset absence epilepsy
→ Global developmental delay, particularly in speech
→ Complex movement disorders, paroxysmal events triggered by exercise
(J. Klepper – Developmental Medicine & Child Neurology 2015, 57: 890–8)
METAglut1™ soon available for clinical use
METAglut1 is a direct and accurate quantification of GLUT1 expression on red cells
A simple blood draw,
no need for fasting
Blood can be
analyzed up to 7 days
A detailed, actionable
Benefits from an exceptional, fast track funding from the French Health Ministry of Health through the Forfait Innovation Scheme, for an early access to the solution for patients.
Germany: available soon through a national partner
Soon in your country
At METAFORA, we work hard to extend our distribution network.
If you have questions: